Department of Otorhinolaryngology - Head and Neck Surgery, Turku University Hospital, Turku, Finland
Otorhinolaryngology, Faculty of Medicine, University of Turku, Turku, Finland.
BMJ Open. 2022 Sep 14;12(9):e062722. doi: 10.1136/bmjopen-2022-062722.
The standard surgical treatment for recurrent or chronic tonsillitis is extracapsular tonsillectomy. Recent studies show that intracapsular tonsillectomy has the potential to reduce the postoperative morbidity of patients undergoing tonsil surgery. The Finnish Intracapsular Tonsillectomy (FINITE) trial aims to provide level I evidence to support the hypothesis that the recovery time from tonsil surgery can be reduced with intracapsular tonsillectomy. Additionally, from this trial, major benefits in quality of life, reduction of postoperative complications, treatment costs and throat symptoms might be gained.
The FINITE trial is a prospective, randomised, controlled, patient-blinded, three-arm clinical trial. It is designed to compare three different surgical methods being extracapsular monopolar tonsillectomy versus intracapsular microdebrider tonsillectomy versus intracapsular coblation tonsillectomy in the treatment of adult patients (16-65 years) suffering from recurrent or chronic tonsillitis. The study started in September 2019, and patients will be enrolled until a maximum of 200 patients are randomised. Currently, we are in the middle of the study with 125 patients enrolled as of 28 February 2022 and data collection is scheduled to be completed totally by December 2027. The primary endpoint of the study will be the recovery time from surgery. Secondary endpoints will be the postoperative pain scores and the use of analgesics during the first 3 weeks of recovery, postoperative haemorrhage, quality of life, tonsillar remnants, need for revision surgery, throat symptoms, treatment costs and sick leave. A follow-up by a questionnaire at 1-21 days and at 1, 6, 24 and 60 months will be conducted with a follow-up visit at the 6-month time point.
Ethical approval was obtained from the Medical Ethics Committee of the Hospital District of Southwest Finland (reference number 29/1801/2019). Results will be made publicly available in peer-reviewed scientific journals.
NCT03654742.
对于复发性或慢性扁桃体炎,标准的手术治疗方法是包膜外扁桃体切除术。最近的研究表明,扁桃体囊内切除术有可能降低接受扁桃体手术的患者的术后发病率。芬兰囊内扁桃体切除术(FINITE)试验旨在提供一级证据支持以下假设:通过扁桃体囊内切除术可以缩短扁桃体手术的恢复时间。此外,通过这项试验,可能会在生活质量、减少术后并发症、治疗成本和咽喉症状方面获得主要益处。
FINITE 试验是一项前瞻性、随机、对照、患者盲法、三臂临床试验。它旨在比较三种不同的手术方法,即包膜外单极扁桃体切除术、扁桃体囊内微动力切除术和扁桃体囊内等离子切除术,用于治疗患有复发性或慢性扁桃体炎的成年患者(16-65 岁)。该研究于 2019 年 9 月开始,预计将招募最多 200 名患者。截至 2022 年 2 月 28 日,我们已经招募了 125 名患者,数据收集计划于 2027 年 12 月全部完成。该研究的主要终点是手术恢复时间。次要终点将是术后疼痛评分和术后 3 周内使用镇痛药的情况、术后出血、生活质量、扁桃体残体、需要再次手术、咽喉症状、治疗成本和病假。将在术后 1-21 天和 1、6、24 和 60 个月进行问卷调查,并在 6 个月时进行随访。
该研究已获得西南芬兰地区医院区医学伦理委员会的批准(编号 29/1801/2019)。结果将在同行评议的科学期刊上公开发布。
NCT03654742。